11th Feb 2016 15:57
LONDON (Alliance News) - Biofrontera AG said Thursday its phase III trials for its drug candidate BF-200 ALA showed very high efficacy, positive safety and "excellent" aesthetic outcomes for the treatment of skin cancer.
The biopharmaceutical company said the three trials were conducted on a total of 779 patients with actinic keratosis, a superficial skin cancer caused by sun damage, testing the drug against placebos as well as Metvix, a drug that has been approved for treatment in the European Union.
The full results will be announced at the 14th South Beach Symposium in Florida on Friday.
"These results from our three Phase III trials evaluating BF-200 ALA in actinic keratosis are substantial as they demonstrate the clinical viability of our novel combination therapy system," said Hermann Lubbert, chief executive of Biofrontera AG.
Biofrontera AG shares were 0.1% up at EUR2.00 in London on Thursday afternoon.
By Hannah Boland; [email protected]; @Hannaheboland
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
B8F.L